EQUILLIUM, INC. Proceeds from Debt, Net of Issuance Costs
EQUILLIUM, INC. (EQ) reported Proceeds from Debt, Net of Issuance Costs of $9.88 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2021-03-24
- EQUILLIUM, INC. proceeds from debt, net of issuance costs for the quarter ending 2019-12-31 was -$60.00K.
- EQUILLIUM, INC. proceeds from debt, net of issuance costs for fiscal 2019 was $9.88M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|
| 2019-12-31 | -$60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $9.88M 10-K · filed 2021-03-24 | |
| 2019-09-30 | $9.94M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |